Centessa Pharmaceuticals (CNTA) Beginning Cash Balance (2021 - 2022)

Centessa Pharmaceuticals (CNTA) reported Beginning Cash Balance of $261000.0 for Q1 2022, up 2275.0% quarter-over-quarter from -$12000.0 in Q4 2021.

Centessa Pharmaceuticals (CNTA) Beginning Cash Balance (2021 - 2022) Analysis & Trends

Centessa Pharmaceuticals (CNTA) has 2 years of Beginning Cash Balance data on file, last reported at $261000.0 in Q1 2022.

Beginning Cash Balance for Q1 2022 came in at $261000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $249000.0 (changed N/A YoY), and the FY2021 annual result was $283000.0, changed N/A from the prior year.
Beginning Cash Balance improved to $261000.0 in Q1 2022 per CNTA's latest filing, from -$12000.0 in the prior quarter.
Over five years, Beginning Cash Balance peaked at $261000.0 in Q1 2022 and troughed at -$12000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Centessa Pharmaceuticals	6.15 Bn	6.15 Bn	-

Download Data